Cholesterol and Alzheimer's—Charging Fast But Still at a Distance from Solid Answers
genetics issue is covered in our Neurobiology of Lipids abstracts article Frankfurt, Germany Meeting (26
Upcoming Webinars
No Upcoming Webinars AvailableALL WEBINARS
58 RESULTS
You searched 26.
Sort By:
- Most Recent
- Most Commented
- Most Relevant
Can We (Should We?) Develop “Smart Drugs” to Stave Off Age-Related Memory Loss?
On 26 February 2009, we held a Webinar/Live Discussion with a slide presentation by Scott Small
Alzheimer Immunotherapy Trial Grounded: Time to Reassess Safety and Vaccine Design
Giulio Maria Pasinetti led this live discussion on 5 March 2002. Readers are invited to submit additional comments by using our Comments form at the bottom of the page. Background Reading by Giulio Maria Pasinetti et al. (pdf file: download free Acrob
New Frontier: Developing Outcome Measures for Pre-dementia Trials
See questions answered by Suzanne Hendrix As researchers push into the frontier of early-stage and preventative Alzheimer's disease clinical trials, they will have to measure whether a drug works in people who do not have dementia yet. Traditional ou
Two New Sets of Diagnostic Criteria—Which Is Right for Your Clinic?
On 19 April 2011, the National Institute on Aging (NIA) and the Alzheimer’s Association (AA) published new guidelines for the diagnosis of Alzheimer’s disease (AD) and its pre-dementia and preclinical phases (see ARF related news story on McKhann et al.,
Sports Concussions, Dementia, and APOE Genotyping: What Can Scientists Tell the Public? What’s Up for Research?
This live discussion was held on 26 June 2008 with Sam Gandy, Mount Sinai School of Medicine, New
Cerebrometabolic Deficiency in Alzheimer's Disease
J Molec Neurosci 2001;(17):361-369. Abstract. 26. Curti D, Rognoni F, Gasparini L, Cattaneo A, Paolillo M,
Targeting Tumor Necrosis Factor—A Therapeutic Strategy for AD
prevent TNFα transcription (25,26). A possible post-translational therapeutic target in AD is TACE (TNFα
Untapped Resource? New Study to Boost Acceptance of CSF Analysis
indicated that the incidence of all LP complications is low. Led by Blennow, the study found that only 2.6
Picking up the Pieces of Parkin
Dubiel, W., and Gordon, C., Regulatory subunit interactions of the 26S proteasome, a complex problem.
The Neuroplasticity Theory of Alzheimer's Disease
dependent secretion of b-amyloid: roles of b-amyloid in synaptic transmission. Soc Neurosci Abstr. 26, 491
How the Other Half Lives—Or the What, How, and Where of the AβPP Intracellular Domain
Frank LaFerla led this live discussion on 20 September 2002. Readers are invited to submit additional comments by using our Comments form at the bottom of the page. Transcript: Live discussion held 20 September 2002, featuring Frank LaFerla of the Univers
Intraneuronal Aβ Accumulation—More Evidence, Less Controversy?
Gunnar Gouras led this live discussion on 26 November 2002. Readers are invited to submit
Axonal Transport Hypothesis Moves On to Implicate Presenilin
This live discussion is an update of last year's initial Live Discussion of axonal transport as an underlying factor in neurodegeneration. Jorge Busciglio and Scott Brady led this live discussion on 17 June 2003. Readers are invited to submit additio
How Does Excess Aβ Leave the Brain, How Does It Get In, And Can We Trap It Outside?
Neurobiol Dis. 1997;4:27-34. Abstract 26. Poduslo JF, Curran GL. Amyloid-b peptide as a vaccine for
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.
Current Filters
- Keyword: 26. x